168 related articles for article (PubMed ID: 25481527)
1. Predictive markers of response to neoadjuvant therapy in rectal cancer.
García-Flórez LJ; Gómez-Álvarez G; Frunza AM; Barneo-Serra L; Martínez-Alonso C; Fresno-Forcelledo MF
J Surg Res; 2015 Mar; 194(1):120-6. PubMed ID: 25481527
[TBL] [Abstract][Full Text] [Related]
2. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer.
Huh JW; Lee JH; Kim HR
Ann Surg; 2014 Mar; 259(3):508-15. PubMed ID: 23787217
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
5. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of stromal cell-derived factor 1α expression is associated with the resistance to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: angiogenic markers of neoadjuvant chemoradiation.
Kim HJ; Bae SB; Jeong D; Kim ES; Kim CN; Park DG; Ahn TS; Cho SW; Shin EJ; Lee MS; Baek MJ
Oncol Rep; 2014 Dec; 32(6):2493-500. PubMed ID: 25241658
[TBL] [Abstract][Full Text] [Related]
8. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
12. [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
Sun Y; Chi P; Xu B; Lin H; Lu X; Huang Y; Xu Z; Huang S; Jiang C
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jun; 17(6):556-60. PubMed ID: 24953361
[TBL] [Abstract][Full Text] [Related]
13. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
[TBL] [Abstract][Full Text] [Related]
14. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.
Min BS; Choi YJ; Pyo HR; Kim H; Seong J; Chung HC; Rha SY; Kim NK
Arch Surg; 2008 Nov; 143(11):1091-7; discussion 1097. PubMed ID: 19015468
[TBL] [Abstract][Full Text] [Related]
16. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
17. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
Kim JS; Kim JM; Li S; Yoon WH; Song KS; Kim KH; Yeo SG; Nam JS; Cho MJ
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):195-200. PubMed ID: 16839708
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy.
Lee-Kong SA; Ruby JA; Chessin DB; Pucciarelli S; Shia J; Riedel ER; Nitti D; Guillem JG
Dis Colon Rectum; 2012 Sep; 55(9):990-5. PubMed ID: 22874607
[TBL] [Abstract][Full Text] [Related]
20. Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Sun Z; Adam MA; Kim J; Shenoi M; Migaly J; Mantyh CR
J Am Coll Surg; 2016 Apr; 222(4):367-74. PubMed ID: 26897480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
